160 related articles for article (PubMed ID: 21924258)
1. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis.
Vasko R; Mueller GA; von Jaschke AK; Asif AR; Dihazi H
Eur J Pharmacol; 2011 Nov; 670(1):50-7. PubMed ID: 21924258
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
3. Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues.
Perego RA; Bianchi C; Corizzato M; Eroini B; Torsello B; Valsecchi C; Di Fonzo A; Cordani N; Favini P; Ferrero S; Pitto M; Sarto C; Magni F; Rocco F; Mocarelli P
J Proteome Res; 2005; 4(5):1503-10. PubMed ID: 16212400
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma.
Craven RA; Stanley AJ; Hanrahan S; Dods J; Unwin R; Totty N; Harnden P; Eardley I; Selby PJ; Banks RE
Proteomics; 2006 May; 6(9):2853-64. PubMed ID: 16596713
[TBL] [Abstract][Full Text] [Related]
5. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation.
D'Aguanno S; D'Alessandro A; Pieroni L; Roveri A; Zaccarin M; Marzano V; De Canio M; Bernardini S; Federici G; Urbani A
J Proteome Res; 2011 Feb; 10(2):416-28. PubMed ID: 21128686
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Li Y; Zhang CY; Luo KJ; Zang X; Li YF; Guan XY; Fu JH
Int J Oncol; 2010 Jan; 36(1):265-74. PubMed ID: 19956855
[TBL] [Abstract][Full Text] [Related]
7. Quantitative differences in protein expression between cisplatin sensitive C0C1 ovarian carcinoma cells and cisplatin resistant C0C1/DDP cells.
Wang HX; Sun W; Li HL; Zhang WY
Chin Med J (Engl); 2009 Apr; 122(7):865-9. PubMed ID: 19493403
[No Abstract] [Full Text] [Related]
8. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
9. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR.
Yang YX; Xiao ZQ; Chen ZC; Zhang GY; Yi H; Zhang PF; Li JL; Zhu G
Proteomics; 2006 Mar; 6(6):2009-21. PubMed ID: 16525997
[TBL] [Abstract][Full Text] [Related]
10. Identification of constitutive and gamma-interferon- and interleukin 4-regulated proteins in the human renal carcinoma cell line ACHN.
Sullivan CM; Smith DM; Matsui NM; Andrews LE; Clauser KR; Chapeaurouge A; Burlingame AL; Epstein LB
Cancer Res; 1997 Mar; 57(6):1137-43. PubMed ID: 9067284
[TBL] [Abstract][Full Text] [Related]
11. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
12. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH
Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393
[TBL] [Abstract][Full Text] [Related]
13. Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.
Yiu CC; Sasano H; Ono K; Chow LW
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S79-89. PubMed ID: 20374034
[TBL] [Abstract][Full Text] [Related]
14. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
16. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line.
Gu Y; Fan S; Xiong Y; Peng B; Zheng G; Yu Y; Ouyang Y; He Z
FEBS Lett; 2011 Mar; 585(6):881-7. PubMed ID: 21334329
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells.
Hirano G; Izumi H; Kidani A; Yasuniwa Y; Han B; Kusaba H; Akashi K; Kuwano M; Kohno K
Mol Cancer Res; 2010 Jun; 8(6):864-72. PubMed ID: 20530585
[TBL] [Abstract][Full Text] [Related]
18. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y
Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219
[TBL] [Abstract][Full Text] [Related]
19. Acute application of cisplatin affects methylation status in neuroblastoma cells.
Tabata K; Sakai H; Nakajima R; Saya-Nishimura R; Motani K; Okano S; Shibata Y; Abiko Y; Suzuki T
Oncol Rep; 2011 Jun; 25(6):1655-60. PubMed ID: 21424131
[TBL] [Abstract][Full Text] [Related]
20. Nox4 inhibition enhances the cytotoxicity of cisplatin in human renal cancer cells.
Chang G; Chen L; Lin HM; Lin Y; Maranchie JK
J Exp Ther Oncol; 2012; 10(1):9-18. PubMed ID: 22946340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
